Earl R T, Hunneyball I M, Billett E E, Mayer R J
Department of Biochemistry, Queen's Medical Centre, University of Nottingham, UK.
J Pharm Pharmacol. 1988 Mar;40(3):166-70. doi: 10.1111/j.2042-7158.1988.tb05211.x.
Fusogenic vesicles reconstituted from the envelopes of Sendai virus particles were injected into rabbit knee joints (both normal and experimentally arthritic) to evaluate the in-vivo biocompatibility of these putative drug carriers. The reconstituted Sendai virus envelopes (RSVE) were greater than 80% retained within the arthritic knee joints after 24 h and studies with 125I- and fluorescein-labelled RSVE both showed association of the vesicles with the synovia of arthritic and healthy joints. However, RSVE were found to cause inflammation after intra-articular injection, as judged by joint swelling and histological assessment, and these effects were exacerbated by successive administrations. RSVE-entrapped methotrexate, whether free or conjugated to human serum albumin, was ineffective in preventing the irritancy of RSVE or in reducing the chronic inflammation in joints affected by an experimentally induced arthritis.
将从仙台病毒颗粒包膜重构的融合囊泡注射到兔膝关节(包括正常膝关节和实验性关节炎膝关节)中,以评估这些假定的药物载体在体内的生物相容性。重构的仙台病毒包膜(RSVE)在24小时后有超过80%保留在关节炎膝关节内,对用125I和荧光素标记的RSVE的研究均显示囊泡与关节炎和健康关节的滑膜有关联。然而,通过关节肿胀和组织学评估判断,发现RSVE在关节内注射后会引起炎症,并且这些效应在连续给药后会加剧。包裹甲氨蝶呤的RSVE,无论甲氨蝶呤是游离的还是与人血清白蛋白偶联的,在预防RSVE的刺激性或减轻实验性诱导关节炎所影响关节的慢性炎症方面均无效。